A coronavirus vaccine developed by Pfizer is more than 90 percent effective, according to the first look at data from a late-stage U.S. trial involving nearly 44,000 participants.
An analysis of 94 trial participants who contracted Covid-19 showed that the vaccine was 94 percent effective, the company and its partner BioNTech said in a press release Monday.
The pair added that they expect to apply to the FDA for an emergency-use authorization before the end of the month, after they have collected sufficient data on the vaccine’s safety.
The better-than-expected result is the first Phase III data from any of the four candidates now in the final stage of testing in the U.S.
